Literature DB >> 4591152

A new sustained-release tablet formulation of procainamide.

D Fremstad, S Dahl, S Jacobsen, P K Lunde, K J Nådland, A A Marthinsen, T Waaler, K H Landmark.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4591152     DOI： 10.1007/bf00644741

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  11 in total

1.  A familial study of procainamide-induced systemic lupus erythematosus. A question of pharmacogenetic polymorphism.

Authors:  E J Lappat; M J Cawein
Journal:  Am J Med       Date:  1968-12       Impact factor: 4.965

2.  Lupus-like syndrome, with persistent immunological abnormalities, related to procainamide therapy.

Authors:  T P Anastassiades; J A Miliiken
Journal:  Can Med Assoc J       Date:  1972-08-19       Impact factor: 8.262

3.  Antiarrhythmic prophylaxis with procainamide in acute myocardial infarction.

Authors:  J Koch-Weser; S W Klein; L L Foo-Canto; J A Kastor; R W DeSanctis
Journal:  N Engl J Med       Date:  1969-12-04       Impact factor: 91.245

4.  Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine.

Authors:  H M Perry; E M Tan; S Carmody; A Sakamoto
Journal:  J Lab Clin Med       Date:  1970-07

5.  [Arrhythmia prophylaxis with procanamide: inadequate dosage?].

Authors:  P Collste; E Karlsson; B Norlander; J Sievers; F Sjöqvist
Journal:  Lakartidningen       Date:  1972-06-12

6.  Relation of hydralazine plasma concentration to dosage and hypotensive action.

Authors:  R Zacest; J Koch-Weser
Journal:  Clin Pharmacol Ther       Date:  1972 May-Jun       Impact factor: 6.875

7.  Procainamide dosage schedules, plasma concentrations, and clinical effects.

Authors:  J Koch-Weser; S W Klein
Journal:  JAMA       Date:  1971-03-01       Impact factor: 56.272

8.  Pharmacokinetic of procainamide in man.

Authors:  J Koch-Weser
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

9.  Metabolism of procainamide in rhesus monkey and man.

Authors:  J Dreyfuss; J T Bigger; A I Cohen; E C Schreiber
Journal:  Clin Pharmacol Ther       Date:  1972 May-Jun       Impact factor: 6.875

10.  Intermittent intravenous procaine amide to treat ventricular arrhythmias. Correlation of plasma concentration with effect on arrhythmia, electrocardiogram, and blood pressure.

Authors:  E G Giardina; R H Heissenbuttel; J T Bigger
Journal:  Ann Intern Med       Date:  1973-02       Impact factor: 25.391
View more
  6 in total

1.  Procainamide absorption studies to test the feasibility of using a sustained-release preparation.

Authors:  T R Shaw; C R Kumana; C M Kaye; C Padgham; T Kaspi; J Hamer
Journal:  Br J Clin Pharmacol       Date:  1975-12       Impact factor: 4.335

2.  Acetylation of procaine amide in man. A preliminary communication.

Authors:  E Karlsson; G Aberg; P Collste; L Molin; B Norlander; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1975       Impact factor: 2.953

3.  Comparison of the acetylation of procainamide and sulfadimidine in man.

Authors:  K Frislid; M Berg; V Hansteen; P K Lunde
Journal:  Eur J Clin Pharmacol       Date:  1976-03-22       Impact factor: 2.953

4.  A pharmacokinetic comparison of two sustained-release oral procainamide preparations.

Authors:  P Hore; P Bones; T Rollinson; H Ikram
Journal:  Br J Clin Pharmacol       Date:  1979-09       Impact factor: 4.335

Review 5.  Clinical pharmacokinetics of procainamide.

Authors:  E Karlsson
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

6.  Significance of the acetylation phenotype and the therapeutic effect of procainamide.

Authors:  P Schröder; N A Klitgaard; E Simonsen
Journal:  Eur J Clin Pharmacol       Date:  1979-02-19       Impact factor: 2.953
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.